PLUS THERAPEUTICS PSTV 深 沪
等待开盘 12-19 09:30:00 美东时间
0.5515
-0.028
-4.91%
华盛通- 最 高0.5998
- 今 开0.5945
- 成交量 512.37万股
- 最 低 0.54
- 昨 收 0.58
- 总市值 7555.55万
- 52周最高 2.3099
- 市盈率 静 --
- 换手率 3.74%
- 52周最低 0.1634
- 委 比 -96.43%
- 总股本 1.37亿
- 历史最高 343.35
- 量 比 0.96
- 振 幅 10.31%
- 历史最低 0.1634
- 每 手 1
- 风险率 0.32%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Plus Therapeutics Announces Expansion of CNSide Team and Issuance of Inducement Grants
Plus Therapeutics, Inc. subsidiary CNSide Diagnostics announced the hiring of Prem Gurnani as Senior Director of Lab Operations and Elaine Luckey as Director of Quality & Regulatory Affairs. Both received stock options and RSUs as part of their compensation. The company expects these hires to enhance its capabilities in addressing the CNS cancer diagnostics market.
12-09 12:30
美股大行评级 | 超配！BETA、BillionToOne获多家机构首予评级；摩根大通上调阿斯麦目标价升至1275美元
今日重点评级关注：RBC Capital：上调Neumora Therapeutics评级至"跑赢大市"，目标价从4美元升至7美元；HC Wainwright & Co.：维持ProMIS Neurosciences"买入"评级，目标价从4美元升至18美元
12-02 09:50
Plus Therapeutics To Present ReSPECT Phase 1 Dose Escalation Study Results For Leptomeningeal Metastases At 2025 SABCS
Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers,
12-01 20:38
美股大行评级 | 最高130美元！11家大行集体上调沃尔玛目标价；戴康工业、Gap、罗斯百货等均或多家大行上调目标价
今日重点评级关注：Canaccord Genuity：维持Fractyl Health"买入"评级，目标价从6美元升至8美元；HC Wainwright & Co.：维持MediWound"买入"评级，目标价从31美元升至36美元
11-24 11:23
Plus Therapeutics' CNSide Diagnostics Signs National Agreement With Humana To Provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration Laboratory Developed Test
CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), announced today that it has signed a national agreement with Humana, Inc. (NYSE:HUM),
11-20 20:34
Plus Therapeutics granted 180-day to regain compliance with Nasdaq
Plus Therapeutics (PSTV) announced on Monday that it has received an additional 180-day extension period from the Nasdaq to regain compliance with the $1.00 minimum bid price requirement as per Nasdaq...
11-17 21:06
Plus Therapeutics Gains Nasdaq Extension for Compliance
Plus Therapeutics ( ($PSTV) ) has provided an announcement. On November 17, 202...
11-17 20:58
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
HC Wainwright & Co. Maintains Buy on Plus Therapeutics, Lowers Price Target to $2
HC Wainwright & Co. analyst Sean Lee maintains Plus Therapeutics (NASDAQ:PSTV) with a Buy and lowers the price target from $3 to $2.
11-03 19:31
Plus Therapeutics Q3 EPS $(0.04) Misses $(0.02) Estimate, Sales $1.397M Miss $1.500M Estimate
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.02) by 100 percent. This is a 89.19 percent increase over losses of $(0.37) per share from
10-31 04:28
